Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sarah, Sloot"'
Autor:
Keiran S.M. Smalley, Hussein Tawbi, Darrin Stuart, Geoffrey T. Gibney, Sarah Sloot, Friedegund Meier, John M. Kirkwood, Uma N. Rao, Alejandro Villagra, Elena B. Pasquale, Jane L. Messina, Vernon K. Sondak, Keith T. Flaherty, Hensin Tsao, Jobin K. John, Inna V. Fedorenko, John M. Koomen, Bin Fang, Meghna Das Thakur, Kim H.T. Paraiso
Supplemental Figure 1. Characterization of the resistant cell lines. Supplemental Figure 2. Quantification of the cell invasion from figure 1D. Supplemental Figure 3. Model showing ligand dependent and independent ephrin signaling. Supplemental Figur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dce9c47489ab84a6f2137134ee8395f
https://doi.org/10.1158/2159-8290.22530725
https://doi.org/10.1158/2159-8290.22530725
Autor:
Jamie L. Weber, Vernon K. Sondak, Geoffrey T. Gibney, James J. Mulé, Jonathan S. Zager, Jacob J. Benedict, Xiuhua Zhao, Keiran S.M. Smalley, Jeffrey S. Weber, Yian A. Chen, Sarah Sloot, Peter A. Forsyth
Publikováno v:
Cancer. 124:297-305
BACKGROUND The development of brain metastases is common for systemic treatment failure in patients with melanoma and has been associated with a poor prognosis. Recent advances with BRAF and immune checkpoint therapies have led to improved patient su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92f5535f75f2e295b5cdf98cdedb1f66
https://doi.org/10.1002/cncr.30946
https://doi.org/10.1002/cncr.30946
Publikováno v:
Cancer causes & control, 23(1), 12-20. SPRINGER
Background Locoregional advanced melanoma poses a complex clinical challenge that requires a multidisciplinary, patient-centered approach. Numerous agents have been studied for their suitability as intralesional therapy in the past decades, but few h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::146343715586e5140150f9b72d0dcd5a
https://doi.org/10.1177/107327481602300104
https://doi.org/10.1177/107327481602300104
Autor:
Yvonne Engels, Alison Gethin, Louise Chopra, Stans Verhagen, Sarah Sloot, Jason W Boland, Kris Vissers, Sam H Ahmedzai, T. Green, John A. Snowden, Andrea Foster, Yousef Ezaydi
Publikováno v:
Supportive Care in Cancer, 23, 3, pp. 671-8
Supportive Care in Cancer
Supportive Care in Cancer, 23(3), 671-678. SPRINGER
Supportive Care in Cancer, 23, 671-8
Supportive Care in Cancer
Supportive Care in Cancer, 23(3), 671-678. SPRINGER
Supportive Care in Cancer, 23, 671-8
Contains fulltext : 153967.pdf (Publisher’s version ) (Open Access) BACKGROUND: Pain is a common symptom in patients with multiple myeloma (MM). Many patients are dependent on analgesics and in particular opioids, but there is limited information o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7132a8198d77a636a77718a7c071a561
https://doi.org/10.1007/s00520-014-2358-1
https://doi.org/10.1007/s00520-014-2358-1
Autor:
Sarah Sloot, Peter A. Forsyth, Jonathan S. Zager, Geoffrey T. Gibney, Jacob J. Benedict, Xiuhua Zhao, Yian A. Chen, Jeffrey S. Weber, Keiran S.M. Smalley, James J. Mulé, Jamie L. Weber, Vernon K. Sondak
Publikováno v:
Cancer. 124(10)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf22ff929884f8f910a9d82763b19f6
https://pubmed.ncbi.nlm.nih.gov/29543320
https://pubmed.ncbi.nlm.nih.gov/29543320
Publikováno v:
Expert Opinion on Pharmacotherapy. 15:2629-2639
Introduction: Intralesional therapy for metastatic melanoma has some advantages over systemic therapy. Local drug administration allows for delivery of an increased concentration of the agent and reduced systemic exposure, thereby increasing local ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::845cabf56d21b50ada3307b825e6ef26
https://doi.org/10.1517/14656566.2014.967682
https://doi.org/10.1517/14656566.2014.967682
Publikováno v:
EXPERT OPINION ON PHARMACOTHERAPY, 15(5), 589-592. TAYLOR & FRANCIS LTD
The clinical development of selective BRAF inhibitors for metastatic BRAF V600 mutant melanoma patients has been a major breakthrough in targeted therapeutics. Objective response rates of approximately 50% have been observed in the Phase III studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb8fa7f150a453b6f7fccf626790e728
https://doi.org/10.1517/14656566.2014.881471
https://doi.org/10.1517/14656566.2014.881471
Autor:
Ricardo J. Gonzalez, Geoffrey T. Gibney, Leslie M. Turner, Ragini R. Kudchadkar, Keiran S.M. Smalley, Timothy W. McCardle, Jacob J. Benedict, Sarah Sloot, Vernon K. Sondak, Jonathan S. Zager, Jeffrey S. Weber, Jane L. Messina, R. C. DeConti
Publikováno v:
Melanoma Research, 26(1), 83-87. LIPPINCOTT WILLIAMS & WILKINS
Selective BRAF inhibitors (BRAFi) yield objective responses in 50% of patients with metastatic BRAF V600E mutant melanoma. Adding an MEK inhibitor increases this response rate to 70%. Limited data are available on the outcomes of unresectable stage I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e16d38f31c0846b2de9e11dd6e633516
https://research.rug.nl/en/publications/e7053d76-4bbe-428d-9d29-4187e5918d44
https://research.rug.nl/en/publications/e7053d76-4bbe-428d-9d29-4187e5918d44
Autor:
Johan Legemaate, Margot Veerman, Wouter K. G. Leclercq, Leslie Thomas, Marc R. Scheltinga, Bram J. Keulers, Sarah Sloot, Saskia Houterman
Publikováno v:
Patient safety in surgery, 10:21. BioMed Central Ltd.
Patient Safety in Surgery
Patient safety in surgery, 10. BioMed Central
Patient Safety in Surgery
Patient safety in surgery, 10. BioMed Central
Background Successfully completing a surgical informed consent process is an important element of the preoperative consult. A previous study of Dutch general surgeons demonstrated that the implementation of SIC did not meet acceptable standards. Howe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffb8aec3e5cbddba144234b80e14f2a7
https://doi.org/10.1186/s13037-016-0110-0
https://doi.org/10.1186/s13037-016-0110-0
Autor:
Dieuwertje E. Kok, Inge M. van Oort, Chris H. Bangma, Geert J.L.H. van Leenders, Lambertus A. Kiemeney, Mark F. Wildhagen, Joep G.H. van Roermund, J. Alfred Witjes, Sarah Sloot, Christina A. Hulsbergen-van de Kaa, Femke Struik
Publikováno v:
BJU International 104 (2009) 3
BJU International, 104(3), 321-325
BJU International, 104, 3, pp. 321-5
BJU International, 104(3), 321-325. Wiley-Blackwell Publishing Ltd
BJU International, 104(3), 321-325
BJU International, 104, 3, pp. 321-5
BJU International, 104(3), 321-325. Wiley-Blackwell Publishing Ltd
Contains fulltext : 80667.pdf (Publisher’s version ) (Closed access) OBJECTIVE: To investigate whether body mass index (BMI) is a prognostic factor for biochemical recurrence (BCR) in Dutch men after radical prostatectomy (RP), as although epidemio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491dd22fb6ead7263c03fe6f37363144
https://doi.org/10.1111/j.1464-410X.2009.08404.x
https://doi.org/10.1111/j.1464-410X.2009.08404.x